Tourmaline Bio (TRML) Price & Analysis

Compare

582 Followers

TRML Stock Chart & Stats

Day’s Range― - ―

52-Week Range$11.56 - $29.79

Previous CloseN/A

Volume43.44K

Average Volume (3M)186.12K

Market Cap

$605.57M

Enterprise Value$172.73M

Total Cash (Recent Filing)$239.23M

Total Debt (Recent Filing)$145.00K

Price to Earnings (P/E)―

Beta1.59

Next Earnings

Nov 06, 2025

EPS Estimate

-0.95

Last Dividend Ex-Date

Oct 20, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.90

Shares Outstanding25,692,268

10 Day Avg. Volume119,383

30 Day Avg. Volume186,117

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.29

Enterprise Value/Revenue4.32K

Enterprise Value/Gross Profit-86.37K

Enterprise Value/Ebitda-1.69

Forecast

1Y Price Target

$52.00

Price Target Upside107.09% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe company reported positive results from the Phase 2 TRANQUILITY trial of pacibekitug for atherosclerotic cardiovascular disease in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease.

Market ValuationTRML is considered undervalued given the meaningful size of the ASCVD market and the scarcity of IL-6 inhibitors in development.

Regulatory ProgressTourmaline Bio has reached alignment with the FDA on its plan to conduct a Phase 2 proof-of-concept trial of pacibekitug in abdominal aortic aneurysm.

Bears Say

Commercial RisksRisks include failure of pacibekitug in clinical trials, failure to secure regulatory approval in the U.S., failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.

Investor SentimentThere is a high short interest of 16% float, which could indicate skepticism among some investors.

Tourmaline Bio News

Tourmaline Bio presents data from ongoing Phase 2 TRANQUILITY trial

Tourmaline Bio (TRML) presented additional data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug in a poster...

4d ago

TRML

Tourmaline Bio reports Q2 EPS (90c), consensus (93c)

“The second quarter of 2025 was a transformative period for Tourmaline, with our first data readout for pacibekitug,”...

23d ago

TRML

Tourmaline Bio’s Promising Drug Developments and Strategic Positioning Make It a Top Pick for 2024

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on TRML stock, giving a Buy rating yesterday....

2d ago

TRML

Tourmaline Bio’s Pacibekitug: A Promising Contender in ASCVD Treatment with Undervalued Potential

Tourmaline Bio, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from...

2d ago

TRML

Tourmaline Bio’s Strategic Advancements and Promising Clinical Trial Results Reinforce Buy Rating

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Tourmaline Bio, with...

21d ago

TRML

Tourmaline Bio’s Promising Developments and Strategic Potential: Analyst Recommends ‘Buy’ Rating

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on TRML stock, giving a Buy rating on...

21d ago

TRML

Tourmaline Bio Reports Positive Trial Results and Strong Cash Position

Tourmaline Bio, Inc. ( ($TRML) ) has released its Q2 earnings. Here is a breakdown of the information...

23d ago

TRML

Tourmaline Bio: Strong Financial Position and Promising Cardiovascular Treatment Pipeline Justify Buy Rating

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Tourmaline Bio today and set a price target...

23d ago

TRML

3 Best Stocks to Buy Now, 7/24/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

APP

Tourmaline Bio management to meet with Piper Sandler

Meeting to be held in New York on July 21 hosted by Piper Sandler. Published first on TheFly...

2M ago

TRML

Tourmaline Bio Releases Updated Corporate Presentation

Tourmaline Bio ( ($TRML) ) has provided an announcement. On June 9, 2025, Tourmaline Bio released an updated...

3M ago

TRML

Tourmaline Bio Elects Directors and Ratifies Auditor

Tourmaline Bio ( ($TRML) ) has shared an announcement. On June 4, 2025, Tourmaline Bio, Inc. held its...

3M ago

TRML

Promising Phase 2 Trial Results and Strategic Advantages Justify Buy Rating for Tourmaline Bio

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio (TRML – Research Report) today and...

3M ago

TRML

Tourmaline Bio announces results from ongoing Phase 2 TRANQUILITY trial

Tourmaline Bio (TRML) announced positive topline results from its ongoing Phase 2 TRANQUILITY trial evaluating quarterly and monthly...

4M ago

TRML

TRML FAQ

What was Tourmaline Bio’s price range in the past 12 months?

Tourmaline Bio lowest stock price was $11.56 and its highest was $29.79 in the past 12 months.

What is Tourmaline Bio’s market cap?

Tourmaline Bio’s market cap is $605.57M.

When is Tourmaline Bio’s upcoming earnings report date?

Tourmaline Bio’s upcoming earnings report date is Nov 06, 2025 which is in 62 days.

How were Tourmaline Bio’s earnings last quarter?

Tourmaline Bio released its earnings results on Aug 13, 2025. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$0.923 by $0.023.

Is Tourmaline Bio overvalued?

According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Tourmaline Bio pay dividends?

Tourmaline Bio pays a Notavailable dividend of $15.118 which represents an annual dividend yield of N/A. See more information on Tourmaline Bio dividends here

What is Tourmaline Bio’s EPS estimate?

Tourmaline Bio’s EPS estimate is -0.95.

How many shares outstanding does Tourmaline Bio have?

Tourmaline Bio has 25,692,268 shares outstanding.

What happened to Tourmaline Bio’s price movement after its last earnings report?

Tourmaline Bio reported an EPS of -$0.9 in its last earnings report, beating expectations of -$0.923. Following the earnings report the stock price went up 3.445%.

Which hedge fund is a major shareholder of Tourmaline Bio?

Currently, no hedge funds are holding shares in TRML

Tourmaline Bio Stock Smart Score

Outperform

Fundamentals

Return on Equity

-29.62%

Trailing 12-Months

Asset Growth

-21.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Tourmaline Bio

Tourmaline Bio (TRML) is a biotechnology company focusing on the development of innovative therapies to address unmet medical needs. The company operates in the biopharmaceutical sector, leveraging cutting-edge scientific research to create novel biologics. Tourmaline Bio is committed to advancing its pipeline of therapeutic candidates through rigorous clinical trials, aiming to deliver transformative treatments to patients worldwide.

Tourmaline Bio (TRML) Earnings & Revenues

Historic Earnings Reports

TRML Stock 12 Month Forecast

Average Price Target

$52.00

▲(107.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","39":"$39","66":"$66","25.5":"$25.5","52.5":"$52.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,25.5,39,52.5,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,26.756923076923076,29.943846153846152,33.13076923076923,36.31769230769231,39.504615384615384,42.691538461538464,45.878461538461536,49.065384615384616,52.252307692307696,55.43923076923077,58.62615384615385,61.81307692307693,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,25.756923076923076,27.943846153846152,30.130769230769232,32.31769230769231,34.504615384615384,36.691538461538464,38.878461538461536,41.065384615384616,43.252307692307696,45.43923076923077,47.62615384615385,49.81307692307692,{"y":52,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,24.44923076923077,25.32846153846154,26.20769230769231,27.086923076923078,27.966153846153848,28.845384615384617,29.724615384615383,30.603846153846156,31.483076923076922,32.362307692307695,33.24153846153846,34.12076923076923,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >